Business
Tenon Medical Announces Treatment of First Patient in Strategic Post Market Clinical Study with Company’s Catamaran(TM) SI Joint Fusion System
Mark H. Stouffer, MD and team from Zion Surgery Center perform first case in St George, UT.This clinical study will assess patient pain scores, fusion as well
About this update from Tenon Medical, Inc.
[{"type":"text","content":"Mark H. Stouffer, MD and team from Zion Surgery Center perform first case in St George, UT.This clinical study will assess patient pain scores, fusion as well as other patient reported outcomes out to 24 monthsLOS GATOS, CA / ACCESSWIRE / November 15, 2022 / Tennon Medical, Inc. (\"Tenon\" or the \"Company\") (NASDAQ:TNON), a company transforming care for patients suffering with certain sacroiliac joint disorders, today announced completion of the first patient treated in the Company's Catamaran SI Joint Fusion System clinical study. Mark H. Stouffer, MD, an orthopedic spine surgeon from St. George Orthopedic Spine in St George, UT. successfully treated the first study patient at Zion Surgery Center on November 14, 2022.The study is a prospective, multi-center, single arm post market study that will evaluate the clinical outcomes of patients with sacroiliac joint disruptions or degenerative sacroiliitis treated with the Catamaran SI Joint Fusion System. Patients will be followed out to 24 months assessing various patient reported outcomes, radiographic assessments, and adverse events.\"The goal of SI joint fusion is to stabilize the joint by reducing associated micromotion that is creating pain. The ability to facilitate a true fusion of the SI joint long term can be a key component to favorable patient outcomes, \"states Mark Stouffer, MD. \"The Catamaran, with its ability to transfix the joint and potentially facilitate bony in-growth through the SI joint is one of the more novel implant designs that we have available to treat patients with SI joint disruption. I look forward to the results of this study which will allow us to continue to assess the clinical effectiveness of this implant and its radiographic profile.\"\"We are extremely appreciative to Dr Stouffer and the team at Zion Surgery Center for completing the first study patient with our Catamaran SI Joint Fusion System. We look forward to our additional study centers and investigators beginning their enrollment as well.\" states Steven M. Foster, President and CEO of Tenon Medical. \"This study represents our continued commitment in validating and differentiating patient outcomes and radiographic assessment with the Catamaran system. It is our strong belief that the Catamaran's single, titanium implant design, that transfixes the ilium and sacrum to stabilize the SI ...